Navigation Links
AcelRx Pharmaceuticals Reports Positive Results From a Phase 2 Clinical Trial of Sublingual Sufentanil NanoTabs(TM) in Treating Post-Operative Pain
Date:12/9/2008

REDWOOD CITY, Calif., Dec. 9 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. today announced positive results from a Phase 2 clinical study evaluating the safety and efficacy of its lead product candidate, ARX-01, for the treatment of moderate-to-severe inpatient acute pain following knee replacement surgery. The primary endpoint evaluated pain intensity (Sum of the Pain Intensity Difference - SPID12) over the 12-hour study period compared to baseline. Results demonstrated that compared to placebo, patients receiving 15 mcg of ARX-01 experienced a statistically significant reduction in pain intensity over the study period, based on the worst observation carried forward imputation method (WOCF), p=0.015. Additionally, at the 15 mcg dose, the study met an important secondary endpoint compared to placebo, the percentage of patient dropouts due to inadequate analgesia, p=0.006. Further, no serious or unexpected adverse events related to ARX-01 were reported in the study.

ARX-01 is a sublingual formulation of the opioid pain medication, sufentanil. ARX-01 is based on the company's proprietary NanoTab(TM) dosage form, which enables delivery of sufentanil by the non-invasive oral transmucosal (sublingual) route.

"We chose a very painful surgery in an elderly patient population to showcase the efficacy and safety of Sublingual Sufentanil NanoTabs in treating acute post-operative pain," said Pamela Palmer, M.D., Ph.D., chief medical officer of AcelRx Pharmaceuticals. "The superior attributes of both the drug and the dosage form enabled these highly encouraging Phase 2 results."

This multicenter, double-blind, randomized, placebo-controlled, dose-finding Phase 2 study evaluated the safety and efficacy of ARX-01 in patients undergoing elective unilateral knee replacement surgery. In the study, 101 patients were randomized to receive either placebo or one of three different dosage strengths of ARX-01: 5mcg, 10m
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... October 30, 2014 Investor-Edge has ... (NYSE MKT: ONVO), Medivation Inc. (NASDAQ: MDVN ... Biologics Inc. (NYSE MKT: SYN), and Ironwood Pharmaceuticals Inc. ... be accessed at: http://investor-edge.com/register . On ... 4,549.23, down 0.33%, the Dow Jones Industrial Average declined ...
(Date:10/30/2014)... Chicago, Illinois (PRWEB) October 30, 2014 ... Regenerative and Cellular Medicine Showcase in Chicago, leading ... and Orthopedic Surgeon, Dr. Wade McKenna presented talks ... Effectiveness and Orthopedic Surgical Applications For Stem Cells. ... of amniotic membrane and the properties of AlphaGEMS ...
(Date:10/30/2014)... October 30, 2014 Spartan Bioscience announced ... RX CYP2C19 System . It detects CYP2C19 genetic mutations ... swab. , The Spartan RX CYP2C19 System is the ... been approved in Canada. Due to the system’s ease ... be used by healthcare professionals such as doctors, nurses, ...
(Date:10/30/2014)... CARLSBAD, Calif. , Oct. 30, 2014 Isis ... antisense therapeutics, today announced that management will present a company ... 2014 at 8:30 a.m. ET in Boston, MA. ... will be available on the "Investors & Media" section of ... available on the Isis website within 48 hours and will ...
Breaking Biology Technology:Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2
... WALTHAM, Mass., June 12 Repligen Corporation,(Nasdaq: RGEN ... fiscal,year 2008, ended March 31, 2008. Total revenue for ... $14,074,000 for fiscal year 2007,ended March 31, 2007, an ... consisted primarily of Protein A and SecreFlo(R) product revenue., ...
... Bulletin Board: RPTP), today announced that Ted Daley, President ... the 2008 BIO International Convention to be held June ... Diego, CA., Mr. Daley,s 15-minute corporate overview will ... in room 4 of the CNS/Neurology track., For ...
... Therapeutics, Inc.,(Nasdaq and MTA: CTIC) today announced that a ... newly issued 15% Convertible,Senior Notes due 2011, with an ... to purchase approximately 14.6 million shares of common stock,with ... transaction constitutes a partial exercise of a previously granted,warrant ...
Cached Biology Technology:Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 2Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 3Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 4Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 5Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 6Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 7Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 8Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention 2Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention 3Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention 4Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor 2
(Date:10/30/2014)... German . ... to behave socially? This is one of the central ... studies assumed that it is almost impossible to control ... Planck Institute for Evolutionary Biology have now demonstrated that ... cooperative behaviour of others. However, the possibilities available to ...
(Date:10/30/2014)... North Carolina State University researchers have developed a suite ... between dogs and humans, which has applications in everything ... our pets. , "We,ve developed a platform for computer-mediated ... to new avenues for interpreting dogs, behavioral signals and ... Dr. David Roberts, an assistant professor of computer science ...
(Date:10/29/2014)... oil and gas production are well over recommended levels ... access journal Environmental Health . High levels of ... is the first to be based on community sampling ... be used to supplement official air-quality monitoring programs. , ... not readily flow to the surface. This is because ...
Breaking Biology News(10 mins):Together we are strong -- or insufferable 2Together we are strong -- or insufferable 3Together we are strong -- or insufferable 4New tech aims to improve communication between dogs and humans 2Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3
... at Duke University and the U.S. Geological Survey (USGS) ... production in Arkansas. "Our results show no discernible ... gas drilling and hydraulic fracturing in this region," said ... Duke,s Nicholas School of the Environment. ...
... become stiff after middle age, a new study has revealed., ... compensate for the effects of obesity. But after middle age, ... body fat rises potentially increasing the risk of dying ... of body fat may be related to the total number ...
... emerged in China in February 2013, and is associated ... than 100 human cases of infection, including at least ... cases of infection were described in Hangzhou, Zhejiang Province, ... were similar to the previously reported cases in China. ...
Cached Biology News:Groundwater unaffected by shale gas production in Arkansas 2Body fat hardens arteries after middle age 2Evidence of host adaptation of avian-origin influenza A virus 2
...
Request Info...
Request Info...
... purification systems provide high speed purification of ... offer increased throughput and reproducible results. The ... mL and KingFisher 96, covering sample volumes ... consists of an instrument, specially designed plastics ...
Biology Products: